Abstract:Rationale: Wear particle-induced periprosthetic osteolysis (PPO) is a common long-term complication of total joint arthroplasty, and represents the major cause of aseptic loosening and subsequent implant failure. Previous studies have identified the central role of osteoclast-mediated bone resorption in the pathogenesis of PPO. Thus, therapeutic approaches of inhibiting osteoclast formation and activity are considered to be of great potential to prevent and treat this osteolytic disease. Hedgehog (Hh) signaling has been shown to play an important role in promoting osteoblast differentiation and bone formation. While Hh signaling is also implicated in regulating osteoclastogenesis, whether it can directly inhibit osteoclast differentiation and bone resorption remains controversial. Moreover, its potential therapeutic effects on PPO have never been assessed. In this study, we explored the cell-autonomous role of Hh signaling in regulating osteoclastogenesis and its therapeutic potential in preventing wear particle-induced osteolysis. Methods: Hh signaling was activated in macrophages by genetically ablating Sufu in these cells using LysM-Cre or by treating them with purmorphamine (PM), a pharmacological activator of Smoothened (Smo). In vitro cell-autonomous effects of Hh pathway activation on RANKL-induced osteoclast differentiation and activity were evaluated by TRAP staining, phalloidin staining, qPCR analyses, and bone resorption assays. In vivo evaluation of its therapeutic efficacy against PPO was performed in a murine calvarial model of titanium particle-induced osteolysis by mu CT and histological analyses. Mechanistic details were explored in RANKL-treated macrophages through Western blot analyses. Results: We found that Sufu deletion or PM treatment potently activated Hh signaling in macrophages, and strongly inhibited RANKL-induced TRAP(+) osteoclast production, F-actin ring formation, osteoclast-specific gene expression, and osteoclast activity in vitro. Furthermore, we found that Sufu deletion or PM administration significantly attenuated titanium particle-induced osteoclast formation and bone loss in vivo. Our mechanistic study revealed that activation of Hh signaling suppressed RANKL-induced activation of JNK pathway and downregulated protein levels of two key osteoclastic transcriptional factors, c-Fos and its downstream target NFATc1. Conclusions: Both genetic and pharmacological activation of Hh signaling can cell-autonomously inhibit RANKL-induced osteoclast differentiation and activity in vitro and protect against titanium particle-induced osteolysis in vivo. Mechanistically, Hh signaling hinders osteoclastogenesis partly through suppressing the JNIQc-Fos-NFATc1 cascade. Thus, Hh signaling may serve as a promising therapeutic target for the prevention and treatment of PPO and other osteolytic diseases.

Inhibition of Titanium-Particle-induced Inflammatory Osteolysis after Local Administration of Dopamine and Suppression of Osteoclastogenesis Via D2-like Receptor Signaling Pathway.

Platelet-Derived Growth Factor-Bb Attenuates Titanium-Particle-Induced Osteolysis in Vivo

The Dopamine D1 Receptor Attenuates Titanium Particle-Induced Inhibition of Osteogenesis by Activating the Wnt Signaling Pathway

Protective effects of COX-2 inhibitor on titanium-particle-induced inflammatory osteolysis via the down-regulation of RANK/RANKL.

Role of Cannabinoid Receptor 2 Selective Antagonist in Titanium Particles-Induced Inflammatory Osteolysis

Inhibition Of Titanium Particle-Induced Inflammatory Osteolysis Through Inactivation Of Cannabinoid Receptor 2 By Am630

Is there another possible approach to inhibit wear particles-induced inflammatory osteolysis?

Stevioside Prevents Wear Particle-Induced Osteolysis by Inhibiting Osteoclastogenesis and Inflammatory Response via the Suppression of TAK1 Activation.

The Prevention of Titanium-Particle-induced Osteolysis by OA-14 Through the Suppression of the P38 Signaling Pathway and Inhibition of Osteoclastogenesis.

Effects of Local and Systemic Alendronate Delivery on Wear Debris-Induced Osteolysis in Vivo

Protection against titanium particle induced osteolysis by cannabinoid receptor 2 selective antagonist.

Controlled release of dopamine coatings on titanium bidirectionally regulate osteoclastic and osteogenic response behaviors

Melatonin Attenuates Titanium Particle-Induced Osteolysis Via Activation of Wnt/β-catenin Signaling Pathway

20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis Via MAPK and NF-κB Signaling Pathways

Genetic and pharmacological activation of Hedgehog signaling inhibits osteoclastogenesis and attenuates titanium particle-induced osteolysis partly through suppressing the JNK/c-Fos-NFATc1 cascade.

Low-Dose Captopril Inhibits Wear Debris-Induced Inflammatory Osteolysis

Dopamine promotes osteogenic differentiation of PDLSCs by activating DRD1 and DRD2 during orthodontic tooth movement via ERK1/2 signaling pathway

Simple 3,4-Dihydroxy- L -Phenylalanine Surface Modification Enhances Titanium Implant Osseointegration in Ovariectomized Rats

DAPT inhibits titanium particle-induced osteolysis by suppressing the RANKL/Notch2 signaling pathway

DAPT inhibits titanium particle-induced osteolysis by suppressing the RANKL/Notch2 signaling pathway.

Simple 3,4-Dihydroxy-&Itl&It-Phenylalanine Surface Modification Enhances Titanium Implant Osseointegration In Ovariectomized Rats